News Release

2016.12.19

Notification of application for manufacturing and marketing approval of HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)

2016.11.21

Notification of acquisition state and acquisition end of company’s own shares.

2016.11.04

Notification of regarding acquisition of own shares.(Acquisition of company’s own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law)

2016.10.11

FY02/2017 Q2 Results Earnings Release Presentation

2016.09.05

Notification of the commencement of the Phase III clinical study of HP-3070 in the United States (a transdermal drug for the treatment of Schizophrenia)

2016.08.29

Notification of the results of the Phase II / III clinical study of HP-3150 in Japan for “cancer pain” (an analgesic transdermal drug containing NSAIDs)

2016.07.26

Notification of the Noven Pharmaceuticals, Inc. assigns rights for Brisdelle® (Paroxetine) Capsules and Pexeva® (Paroxetine Mesylate) Tablets

2016.07.25

Notice Concerning Finalization of Details of Issuance of Stock Options as Compensation

2016.07.25

Notification of the results of Phase III clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)

2016.07.25

Notification of the results of Phase II clinical study of HP-3150 in Japan for “Lower back pain” (an analgesic transdermal drug containing NSAIDs)

2016.07.08

FY02/2017 Q1 Results Earnings Release Presentation

2016.07.08

Notice Concerning Issuance of Stock Options as Compensation

2016.07.08

Announcement Regarding Disposition of Treasury Share through Third-Party Allotment

2016.04.08

FY02/2016 Q4 Results Earnings Release Presentation

2016.04.08

Announcement Regarding Disposition and Acquisition of Treasury Share through Third-Party Allotment

2016.04.08

Announcement of Dividend of Surplus in the Fiscal Year Ended February 2016 (114th Fiscal Year)

2016.01.08

FY02/2016 Q3 Results Earnings Release Presentation